ZTS

$115.67-0.32 (-0.28%)

Market ClosedAs of Mar 20, 8:03 PM UTC

Zoetis Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$115.67
Potential Upside
75%
Whystock Fair Value$202.43
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and int...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$50.97B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.25
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
78.41%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.94

Recent News

Zacks
Mar 19, 2026

Wall Street Analysts See Zoetis (ZTS) as a Buy: Should You Invest?

The average brokerage recommendation (ABR) for Zoetis (ZTS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
StockStory
Mar 18, 2026

Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Zoetis (NYSE:ZTS)

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Insider Monkey
Mar 18, 2026

What Makes Zoetis (ZTS) an Investment Bet?

Diamond Hill Capital, an investment management company, released its “Mid Strategy” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fourth quarter posted another period of favorable gains for equity markets, with small and large cap positions being stronger performers, returning 2.19% and 2.41%. While the mid-cap range was a […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 17, 2026

Zoetis Cuts Guidance As Librela Safety Questions Test Growth Story

Zoetis (NYSE:ZTS) reduced its full year guidance after raising safety concerns around its osteoarthritis drug Librela. Management said it intends to address questions on Librela with science based evidence on safety and efficacy. The update has drawn attention because Librela is an important product within Zoetis's animal health portfolio. For investors watching Zoetis at a share price of $118.15, the guidance cut tied to Librela comes on top of a weak longer term share performance. The...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 16, 2026

Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

Zoetis (ZTS) closed the most recent trading day at $118.15, moving +2.19% from the previous trading session.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.